Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1990-12-14
|
pubmed:abstractText |
Nine double-blind studies comparing remoxipride to haloperidol in the treatment of acute schizophrenia formed the basis of this analysis. All studies followed a basic protocol with the main assessments performed regularly during the 4-6 week trial period according to the same methodology, thus allowing the data to be pooled. The results showed that remoxipride in a daily dose of 150-600 mg had a therapeutic effect comparable to that of haloperidol (5-45 mg/day), both on positive and negative symptoms. There was a clear advantage for remoxipride over haloperidol with regard to adverse events/symptoms, particularly extrapyramidal symptoms, but also drowsiness/somnolence and tiredness/fatigue. Anticholinergic drugs were used consistently less frequently as concomitant medication to alleviate extrapyramidal symptoms in the remoxipride group: the use of sedatives/hypnotics was approximately the same in both groups. Based on these and supportive clinical data, remoxipride seems to have a clinical profile characterized by antipsychotic efficacy in acute schizophrenia, apparently equal to that of haloperidol, and good tolerability in being non-sedative (in terms of drowsiness/somnolence) and with low incidences of extrapyramidal, autonomic, and endocrine symptoms.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0065-1591
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
358
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
92-8
|
pubmed:dateRevised |
2008-2-15
|
pubmed:meshHeading |
pubmed-meshheading:1978500-Adolescent,
pubmed-meshheading:1978500-Adult,
pubmed-meshheading:1978500-Aged,
pubmed-meshheading:1978500-Antipsychotic Agents,
pubmed-meshheading:1978500-Benzamides,
pubmed-meshheading:1978500-Double-Blind Method,
pubmed-meshheading:1978500-Female,
pubmed-meshheading:1978500-Haloperidol,
pubmed-meshheading:1978500-Humans,
pubmed-meshheading:1978500-Male,
pubmed-meshheading:1978500-Middle Aged,
pubmed-meshheading:1978500-Psychiatric Status Rating Scales,
pubmed-meshheading:1978500-Psychotic Disorders,
pubmed-meshheading:1978500-Remoxipride,
pubmed-meshheading:1978500-Schizophrenia,
pubmed-meshheading:1978500-Schizophrenic Psychology
|
pubmed:year |
1990
|
pubmed:articleTitle |
Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.
|
pubmed:affiliation |
Astra Research Centre, Södertälje, Sweden.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|